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The inhibition of human lung fibroblast
proliferation and differentiation by Gs-
coupled receptors is not predicted by the
magnitude of cAMP response
Maxine J. Roberts1, Rebecca E. Broome2, Toby C. Kent2, Steven J. Charlton1,2 and Elizabeth M. Rosethorne1,2*
Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive fibrotic lung disease for which there
is no cure. Current therapeutics are only able to slow disease progression, therefore there is a need to explore
alternative, novel treatment options. There is increasing evidence that the 3′, 5′ cyclic adenosine monophosphate
(cAMP) pathway is an important modulator in the development of fibrosis, with increasing levels of cAMP able to
inhibit cellular processes associated with IPF. In this study we investigate the expression of Gs-coupled G protein-
coupled receptors (GPCR) on human lung fibroblasts (HLF), and explore which can increase cAMP levels, and are
most efficacious at inhibiting proliferation and differentiation.
Methods: Using TaqMan arrays we determined that fibroblasts express a range of Gs-coupled GPCR. The function
of selected agonists at expressed receptors was then tested in a cAMP assay, and for their ability to inhibit
fibroblast proliferation and differentiation.
Results: Expression analysis of GPCR showed that the prostacyclin, prostaglandin E2 (PGE2) receptor 2 and 4,
melanocortin-1, β2 adrenoceptor, adenosine 2B, dopamine-1, and adenosine 2A receptors were expressed in HLF.
Measuring cAMP accumulation in the presence of selected Gs-coupled receptor ligands as well as an adenylyl
cyclase activator and inhibitors of phosphodiesterase showed formoterol, PGE2, treprostinil and forskolin elicited
maximal cAMP responses. The agonists that fully inhibited both fibroblast proliferation and differentiation, BAY60–
6583 and MRE-269, were partial agonists in the cAMP accumulation assay.
Conclusions: In this study we identified a number of ligands that act at a range of GPCR that increase cAMP and
inhibit fibroblast proliferation and differentiation, suggesting that they may provide novel targets to develop new
IPF treatments. From these results it appears that although the cAMP response is important in driving the anti-
fibrotic effects we have observed, the magnitude of the acute cAMP response is not a good predictor of the extent
of the inhibitory effect. This highlights the importance of monitoring the kinetics and localisation of intracellular
signals, as well as multiple pathways when profiling novel compounds, as population second messenger assays
may not always predict phenotypic outcomes.
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Background
Idiopathic pulmonary fibrosis (IPF) is an age-related,
chronic and progressive fibrotic lung disease, with an an-
nual incidence in the UK of 7.44 per 100,000 people,
and a median survival of approximately 3 years from
diagnosis [1]. The current hypothesis is that IPF is a
consequence of aberrant wound healing in response to
repetitive lung injury, resulting in fibrosis rather than re-
pair. The dysregulation of the wound healing response is
thought to cause the development of fibrosis through
excess fibroblast proliferation, fibroblast to myofibro-
blast transdifferentiation (FMT), and extracellular matrix
(ECM) deposition. In the IPF lung, aggregates of prolif-
erating fibroblasts and myofibroblasts, termed “fibroblast
foci”, are a key histopathological finding, which indicate
that fibrosis is actively ongoing [2]. An increased accu-
mulation of ECM and scarring in the lung, causes lung
stiffness and compromises its ability to facilitate normal
gas exchange [3].
A key therapeutic goal in the treatment of IPF is to
reduce tissue fibrosis, which may be achieved by enhan-
cing signals that counteract fibrotic processes, and/or in-
hibit signals and mediators that promote fibrosis. There
are at present two drugs that are now approved for use
in the treatment of IPF; nintedanib and pirfenidone.
Nintedanib inhibits multiple receptor tyrosine kinases
(RTK) [4] and pirfenidone has broad anti-inflammatory/
anti-transforming growth factor β (TGFβ) activity [5, 6].
Although both nintedanib and pirfenidone have been
shown to be efficacious in slowing the progression of
disease [7–10], their non-specific action leads to severe
adverse effects such as diarrhoea, dyspnoea, vomiting
and weight loss, that are dose limiting thereby restricting
their use to the more severe patients. Research to iden-
tify alternative pathways in IPF treatment is essential to
enable the development of safer, more efficacious and
better tolerated drugs.
As RTK predominantly signal through the Ras/mito-
gen-activated protein kinase (MAPK) signalling cascade,
it is likely that this pathway is responsible for many of
the pro-fibrotic responses observed in IPF [11]. There is
increasing evidence that the cyclic adenosine monopho-
sphate (cAMP) pathway can negatively impact MAPK
signalling, via inhibition of extracellular signal–regulated
kinase (ERK) phosphorylation and activation in certain
cell types [12, 13]. This suggests that activation of the
cAMP pathway could provide novel targets to treat IPF.
In support of this, a number of studies have shown that
cAMP can negatively regulate fibroblast function, as
agonists that bind to Gs-coupled G protein-coupled re-
ceptors (GPCR) thus activating adenylyl cyclase (AC)
and increasing levels of cAMP, inhibit lung fibroblast
migration, proliferation and differentiation. For example,
prostaglandin E2 (PGE2) acting at PGE2 receptor 2 (EP2)
and 4 (EP4) and iloprost acting at the prostacyclin (IP) re-
ceptor, were shown to have an inhibitory effect on
proliferation and differentiation of lung fibroblasts, via
cAMP accumulation and protein kinase A (PKA) activa-
tion [14–16]. Additionally, increasing levels of cAMP
through direct activation of AC by forskolin inhibited the
proliferation and differentiation of human embryonic fibro-
blasts [17]. Furthermore, inhibition of phosphodiesterases
(PDE), which catalyse cAMP degradation, by roflumilast or
cilomilast was shown to reduce pulmonary fibrosis in the
bleomycin-induced mouse fibrosis model [18, 19].
The present study was performed in order to evaluate
the anti-proliferative capacity of a range of Gs-coupled
GPCR in order to identify potential new targets to treat
IPF. We have explored the ability of Gs-coupled GPCR
present in HLF to increase global cAMP using high-
throughput compatible, homogenous assay kits. We have
further explored how the observed increases in cAMP ac-
cumulation translate into an ability to inhibit fibroblast
proliferation and differentiation, in order to determine
whether any of the selected GPCR would be suitable for
exploring further as novel targets to treat IPF.
Methods
Materials
Foetal bovine serum (FBS), trypsin-EDTA, Hoechst 33,342,
RNAqueous kit, TURBO DNase and High Capacity RNA-
to-cDNA kit were purchased from Life Technologies
(Paisley, UK). CGS-21680, BMY-45778, BAY60–6583, ilo-
prost, and NECA were purchased from Tocris (Abingdon,
UK). Beraprost was bought from Cayman Chemical
Company (Michigan, USA). PDGF-BB was purchased from
R&D Systems (Minneapolis, USA). MRE-269 (CAS:
475085–57-5) and AGN-205204 (CAS:802906–77-0) were
synthesized in house at Novartis (Horsham, UK). Phospho-
p44/42 ERK1/2 (Thr202/Tyr204) (D13.14.4E) XP® Rabbit
mAb primary antibody was purchased from Cell Signalling
Technology (Leiden, The Netherlands). CF™647-conjugated
Affini-pure goat anti-rabbit IgG and CF™647-conjugated
Affini-pure goat anti-mouse IgG were purchased from
Biotium, Inc., (Fremont, California). Pierce™ LDH Cytotox-
icity Assay Kit and CellEvent™ Caspase-3/7 Red Detection
Reagent were purchased from ThermoFisher (Hemel
Hempstead, UK). Staurosporine was purchased from VWR
International Ltd. (Lutterworth, UK). 96-well white
ViewPlates, AlphaScreen cAMP and DELFIA prolifer-
ations assay kits were purchased from Perkin Elmer
Life Sciences (Massachusetts, USA), 96-well black
ViewPlates were purchased from Corning (New York,
USA), and 384-well black, μ-clear Viewplates were
purchased from Greiner bio-one (Stonehouse, UK).
HitHunter™ cAMP assay kits were purchased from
DiscoverX (Birmingham, UK). All other reagents were
purchased from Sigma Aldrich (Poole, UK).
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Cell culture
All studies were performed on normal human lung
fibroblasts (C-12361), which were purchased from Pro-
mocell (Heidelberg, Germany). HLF were maintained in
DMEM supplemented with 4.5 g L− 1 D-glucose, L-
glutamine, pyruvate, FBS (10% v/v), and 25 mM HEPES
at 37°C, 5% CO2, in a humidified atmosphere. For exper-
iments cells were harvested using trypsin/EDTA and
seeded in their sub-culture medium. Two HLF donors
were used in the functional studies: HLF d91019001.2
and HLF 9017402.1, both from healthy/non-smoker
Caucasian donors.
Receptor expression levels
Expression of GPCR was determined in HLF using high
density, 384-well GPCR TaqMan arrays as previously
described [20]. RNA from 4 fibroblast donors (all from
healthy/non-smoker Caucasian donors) was isolated
using the RNAqueous kit and treated with TURBO
DNase to remove genomic DNA. Using a High Capacity
RNA-to-cDNA kit according to manufacturer’s instruc-
tions to synthesize cDNA. The GPCR array contained
validated primer/probe sets for 367 GPCR. 100 ng of
cDNA was loaded per port and the array was run on an
Applied Biosystems 7900HT fast real-time PCR instru-
ment according to the manufacturer’s instruction. 13
housekeeping genes were included as controls in the
arrays for the purpose of quality control and data nor-
malisation: (ACTB, β-actin; B2M, β-2-microglobin;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
GUSB, β-Glucuronidase; HMBS, hydroxymethylbilane
synthase; HPRT1, hypoxanthine phosphoribosyltransfer-
ase 1; IPO8, importin 8; PGK1, phosphoglycerate kinase
1; POLR2A, RNA polymerase II subunit A; PPIA, pepti-
dylprolyl isomerase A; RPLPO, ribosomal protein lateral
stalk subunit P0; TBP, TATA-Box binding protein;
TFRC, Transferrin Receptor). Data was analyzed using
RQ manager version 1.2 and DataAssist version 2 (Ap-
plied Biosystems) with a Cycle Threshold (CT) set at 0.2
for all samples.
ERK phosphorylation
HLF were seeded overnight at 6000 cells/well in 96-well
black clear bottom plates then starved for 24 h in the
growth medium devoid of all additives. To assess ERK
phosphorylation (pERK), cells were incubated in growth
medium devoid of all additives (+ 0.1% HSA, sterile
filtered) for 30 min with a range of concentrations of
forskolin. After this time, cells were stimulated with an
EC80 concentration of PDGF (3 ng/mL) for 10 min, at
37°C, 5% CO2. After stimulation, cells were fixed in 4%
paraformaldehyde, washed 3× in PBS (with Ca2+/Mg2+),
and incubated with permeabilising blocking buffer (dPBS
(with Ca2+/Mg2+), 10% FBS (v/v), 0.1% Triton X-100 (v/
v)) for 1 h at 37°C. Wells were then washed 3× in wash
buffer (Tris Buffered Saline (TBS), 0.05% (v/v) Tween-
20) and incubated with rabbit anti-pERK1/2 antibody (1:
1000 dilution in blocking buffer overnight at 4°C.
Following 3× wash in wash buffer, wells were incubated
with blocking buffer containing Hoechst to stain for nu-
clear DNA (2 μM), and FITC-conjugated Affini-pure
goat anti-rabbit IgG (1:1000 dilution in blocking buffer)
for 30 min at 37°C. Fluorescence was then quantified on
the InCell2000, using DAPI settings to visualize nuclei
(0.1 s exp) and FITC settings for pERK (2 s exp).
To quantify levels of pERK fluorescence, a standard
Multi-Target Analysis algorithm was used in the INCell
Analyzer Workstation (v3.7.1). To account for the inter-
assay variation in levels of ERK phosphorylation pro-
duced in each experiment, data were normalized to the
EC80 PDGF response.
cAMP accumulation
HLF were grown to confluency in 96-well white View-
Plates, before incubation with a range of agonist concen-
trations, or vehicle, for 2 h at room temperature in
HBSS with 5 mM HEPES, 0.1% w/v HSA, and 5 μM roli-
pram. Rolipram was included in these assays to inhibit
PDE activity, which resulted in increased maximal re-
sponses of cAMP accumulation, without any effect on
EC50 values generated (data not shown). Rolipram was
excluded when measuring cAMP levels in response to
PDE inhibitors. cAMP levels were measured using either
HitHunter cAMP assay or AlphaScreen competition assay
following manufacturer protocol, and were assessed on ei-
ther a BMG LABTEK ClarioStar or a Packard EnVision
plate reader. cAMP concentrations in each well were
determined using a standard curve. To account for the
inter-assay variation in levels of cAMP produced in each
experiment, data were normalized to the maximal forsko-
lin response.
Proliferation
Proliferation of HLF was measured by incorporation of
bromodeoxyuridine (BrdU). HLF were seeded overnight
at 4000 cells/well in 96-well black ViewPlates, before be-
ing starved for 24 h in culture medium devoid of FBS.
Proliferation was measured after incubation with a range
of concentrations of FBS or PDGF, in DMEM supple-
mented with 0.1% w/v HSA, for 24 h.
For anti-remodelling assays using BrdU incorporation,
cells were incubated for 24 h with a range of concentra-
tions of test compounds in the presence of near maximal
concentrations of FBS or PDGF in DMEM supple-
mented with 0.1% w/v HSA. Proliferation was assessed
using the DELFIA BrdU incorporation assay kit follow-
ing manufacturer protocol. Fluorescence was measured
using a Packard EnVision plate reader. To account for
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the inter-assay variation in levels of proliferation in each
experiment, data were normalized to the PDGF or FBS
response.
Fibroblast to myofibroblast transdifferentiation
To assess the differentiation of fibroblasts to the myofi-
broblast phenotype, immunofluorescence was used to
monitor increases in α smooth muscle actin (αSMA).
HLF were seeded overnight at 1000 cells/well in 384-
well black clear bottom plates, before being starved for
24 h growth medium devoid of FBS.
For anti-remodelling assays using FMT, cells were
incubated for 48 h with a range of concentrations of test
compounds and incubated for 48 h, at 37°C, 5% CO2 in
the presence of a near maximal concentration of TGFβ
(0.3 ng/mL), to promote differentiation in in DMEM
supplemented with 0.1% w/v HSA. Following stimulation,
cells were fixed in 4% paraformaldehyde, washed 3× in
PBS (with Ca2+/Mg2+), and incubated with permeabilising
blocking buffer (dPBS (with Ca2+/Mg2+), 10% FBS (v/v), 0.
1% Triton X-100 (v/v)) for 1 h at 37°C. Wells were then
washed 3× in wash buffer (Tris Buffered Saline (TBS), 0.
05% (v/v) Tween-20) and incubated with mouse anti-α
SMA (1:1000 dilution in permeabilising blocking buffer)
for 1 h at room temperature, with gentle shaking. Follow-
ing 3× wash in wash buffer, wells were incubated with
blocking buffer containing Hoechst to stain for nuclear
DNA (2 μM), and FITC-conjugated Affini-pure goat anti-
rabbit IgG (1:1000 dilution in blocking buffer) for 30 min
at 37°C. Fluorescence was then quantified on a widefield
ImageXpress Micro microscope, with a Plan Fluor 20X
objective, DAPI filter cube (excitation 400–418 nm, emis-
sion 435–470 nm), 50 ms exposure time for nuclei, and
FITC filter cube (excitation 467–498 nm, emission 513–
556 nm), 200 ms exposure time for αSMA.
To quantify increases in αSMA fluorescence, a standard
Multi-Wavelength Cell Scoring algorithm was used in
MetaXpress 5.3 software (Molecular Devices, California,
USA). To account for the inter-assay variation in levels of
αSMA expression produced in each experiment, data were
normalized to the response to TGFβ.
Data analysis
Data were analysed using GraphPad Prism (Version 7.
00) and results expressed as mean ± standard error of
mean (SEM), unless otherwise stated. Concentration-
response data were fitted using a four-parameter logistic
equation. Expression of GPCR mRNA is reported as 2
TO - ΔCT compared to the mean Cycle Threshold (CT)
of the housekeeping genes and each value is the
mean ± SD of 4 biological replicates. The Pearson cor-
relation coefficient (r) was determined using the standard
correlation function in GraphPad prism, followed by a
two-tailed T test to determine significance.
Results
Role of cAMP in the inhibition of ERK phosphorylation,
and ERK phosphorylation in proliferation
We first aimed to determine whether cAMP accumula-
tion leads to inhibition of the pERK signal cascade in
HLF, which may in turn suggest a role for cAMP in the
inhibition of proliferation. Inhibition of ERK phosphoryl-
ation by the MEK inhibitor PD0325901 blocked PDGF-
mediated proliferation of HLF. In turn forskolin, which
increases cAMP through direct activation of AC, inhib-
ited PDGF-mediated ERK phosphorylation (Fig. 1). For
this reason, we explored the expression of GPCR in
HLF, in order to determine which receptors would have
the potential to increase cAMP and hence inhibit HLF
proliferation and differentiation.
GPCR expression in HLF
We first established the expression profile of GPCR
mRNA in HLF (See Additional file 1: Table S1) to select
receptors to study further. All GPCR tested were charac-
terised according to the canonical G protein pathway
they are reported to couple to [21]. The Gs-coupled re-
ceptors expressed in HLF from high expression to low
expression were IP, EP2, melanocortin-1 (MC1), β2 adre-
noceptor, adenosine 2B (A2B), EP4, dopamine-1, and ad-
enosine 2A (A2A) (Table 1).
The IP receptor was expressed at the highest level,
with 2TO-ΔCT of 0.053, approaching twice as much
as the second highest expressed receptor EP2, with
2TO-ΔCT of 0.029. All the other receptors expressed
had 2TO-ΔCT that ranged from 0.012 for the MC1
receptor to 0.002 for the A2A receptor. Based on
these results, a range of ligands were chosen that tar-
get these receptors (Table 2).
Fig. 1 Inhibition of ERK1/2 phosphorylation and proliferation.
Concentration effect curves for forskolin-mediated inhibition of ERK
phosphorylation, and PD0325901-mediated inhibition of proliferation in
HLF in the presence of 3 ng/mL PDGF. For each individual experiment,
data were normalised to the maximum amount of ERK phosphorylation
or proliferation after addition of 3 ng/mL PDGF, and are expressed as
means ± SEM for 4 independent experiments
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cAMP signalling in HLF
In order to investigate the functional activity of the re-
ceptors that demonstrated expression at the mRNA
level, cAMP accumulation was measured in HLF in the
presence of selected Gs-coupled GPCR agonists (Fig. 2).
cAMP was monitored using commonly used, high
throughput compatible, homogenous assay systems that
allow quantification of cAMP in both cell media and
lysates. In addition, cAMP accumulation was also inves-
tigated through direct activation of AC and inhibition of
PDE, using forskolin and IBMX or rolipram, respect-
ively. The majority of agonists tested increased cAMP
levels in a concentration-dependent manner, with a
range of potencies and efficacies (see Table 3). However,
targeting the A2A receptor with CGS21680 and the MC1
receptor with α-MSH resulted in no detectable cAMP
response. Furthermore, inhibiting PDE with IBMX or
rolipram resulted in no detectable cAMP accumulation.
Forskolin, formoterol, treprostinil, PGE2 and iloprost
were fully efficacious in this assay, with other ligands
giving partial responses that ranged from 8.76 to 83.3%
of the forskolin response.
Proliferation
To determine if the cAMP response we observed in HLF
was able to inhibit processes associated with airway re-
modelling, we investigated the ability of the same range
of Gs-coupled GPCR agonists, as well as PDE inhibitors
and AC activators, to inhibit HLF proliferation.
We first monitored cell number over time using a
nuclei count assay after treatment with a range of
concentrations of FBS or PDGF for 24, 48, 72, or 96 h
(Additional file 1: Figure S2). There was no detectable
increase in number of HLF after 24 h treatment with ei-
ther of the stimuli used. FBS was capable of stimulating
proliferation in a concentration-dependent manner at
48, 72 and 96 h (Additional file 1: Figure S2A), with
EC50 of 0.62 ± 0.08% v/v at 48 h, and estimated EC50 of
3.42 ± 0.77% v/v, and 4.97 ± 0.92% v/v, respectively. In
contrast, when treated with PDGF, HLF proliferation
was only observed after 72 and 96 h treatment, with
EC50 of 3.77 ± 0.13 ng/ml and 7.26 ± 3.23 ng/ml, respect-
ively (Additional file 1: Figure S2B). The PDGF response
was partial compared to the FBS response, with maximal
proliferation of 29.2 ± 15.2% of the maximal serum re-
sponse observed after 96 h treatment.
HLF were then treated for 48 h with a range of
concentrations of ligands in the presence of an FBS con-
centration (1.8% v/v) that relates to near maximal prolif-
eration (as determined from Additional file 1: Figure
S2A). Agonists and PDE inhibitors inhibited FBS-driven
proliferation with varying levels of efficacy and potency,
however, full concentration-response curves could not
be established for most agonists (Additional file 1: Figure
S3), and therefore accurate EC50 and Emax values could
not be deduced. For this reason, we explored the use of
an alternative assay to monitor fibroblast proliferation.
By monitoring BrdU incorporation into newly synthe-
sized DNA of actively proliferating cells, we demonstrated
that treatment of HLF with FBS or PDGF resulted in in-
creases in proliferation in a concentration-dependent
manner after 24 h incubation (Fig. 3). Similar to the nuclei
Table 1 Ligands used in these studies
Ligand Target Mechanism of action
Iloprost IP = EP1 > EP3 > FP > EP4 > TP > EP2 Agonist
Treprostinil IP > EP2 > EP3 > EP4 > EP1 > TP > FP Agonist
MRE-269 IP Agonist
BMY-45778 IP Agonist
Beraprost IP Agonist
PGE2 EP1–4 Agonist
Misoprostol EP2 > EP3 > EP4 > EP1 Agonist
Butaprost EP2, EP4 Agonist
AGN-205204 EP4 Agonist
α-MSH MC1, MC3, MC4, MC5 Agonist
Formoterol β2 Agonist
Indacaterol β2 Agonist
Salbutamol β2 Agonist
Salmeterol β2 Agonist
NECA A3, A1, A2A, A2B Agonist
CGS-21680 A2A Agonist
BAY60–6583 A2B Agonist
Dopamine D1 = D5 > D3 > D2 > D4 Agonist
Forskolin AC 1–8 Activator
IBMX PDE4, PDE3, PDE1, PDE5, PDE2 Inhibitor
Rolipram PDE4 Inhibitor
Ligands used in this study, their molecular targets and mechanism of action
Table 2 Expression analysis of selected GPCR in normal HLF
Receptor Expression (2 TO – ΔCT)
IP 0.053 ± 0.016
EP2 0.029 ± 0.001
MC1 0.012 ± 0.002
β2 0.008 ± 0.004
A2B 0.007 ± 0.003
EP4 0.004 ± 0.002
Dopamine-1 0.004 ± 0.001
A2A 0.002 ± 0.001
Expression analysis of endogenously expressed Gs-coupled receptors in HLF. High
density 384-well GPCR TaqMan arrays were run on normal HLF to monitor the
expression of a range of Gs-coupled receptors. Expression is reported as 2 TO -
ΔCT compared to the mean Cycle Threshold (CT) of the 13 housekeeping genes
that were included as controls in the arrays, and each value is the mean ± SD of 4
biological replicates
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count assays, PDGF was partial in comparison to FBS,
with maximal proliferation of 41.0 ± 8.62% and 112 ± 5.
49% for PDGF and FBS respectively.
HLF were then treated for 24 h with a range of con-
centrations of ligands in the presence of near maximal
concentration of FBS or PDGF (as determined from
Fig. 3). Targeting the IP, EP2, EP4, β2, A2B, and dopa-
mine receptors, as well as activating AC, inhibited HLF
proliferation with varying degrees of intrinsic activity
and potency (Table 3; Figs. 4 and 5). When inhibiting
serum-driven proliferation, ligands achieved maximal
levels of inhibition ranging from 100% for BAY60–6583
to 29% for butaprost. After treatment with PDGF max-
imal levels of inhibition ranged from 100% for BAY60–
6583 to 38% for NECA. BAY60–6583 was the only
ligand to fully inhibit both FBS- and PDGF-driven pro-
liferation, with other ligands being more efficacious at
inhibiting PDGF-driven proliferation. α-MSH and roli-
pram were incapable of inhibiting the proliferation me-
diated by either stimulus.
In order to confirm that test compounds were directly
inhibiting HLF proliferation rather than promoting cell
death, cell viability was measured using the presence of
caspase-3/7 as markers of apoptosis. None of the com-
pounds tested caused a significant increase in expression
of caspase-3/7, whereas treatment with the toxic com-
pound staurosporine resulted in statistically significant cell
apoptosis (P < 0.001) (See Additional file 1: Table S2).
Fibroblast to myofibroblast transdifferentiation
IPF is driven by a number of pro-fibrotic processes, there-
fore we next aimed to determine if the same agonists were
also capable of inhibiting another key component of fibro-
sis, TGFβ-induced FMT. TGFβ is a key driver of fibrosis
Fig. 2 Receptor-mediated cAMP accumulation. Concentration effect curves for cAMP accumulation in HLF after treatment with a range of agonists
targeting (a) IP receptor, (b) EP receptor, (c) β2 adrenoceptor, (d) other GPCR and (e) non-receptors. Data for each individual experiment were normalized
to maximal cAMP accumulation observed with 10 μM forskolin, and are expressed as mean ± SEM for at least 3 independent experiments
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and was able to robustly promote FMT in HLF with EC50
equal to 0.07 ± 0.01 ng/mL (data not shown).
In order to test the ability of compounds to inhibit
FMT, HLF were treated for 48 h with a range of concen-
trations of the selected ligands in the presence of a
TGFβ concentration (0.3 ng/mL) that relates to near
maximal FMT. Agonists and PDE inhibitors inhibited
TGFβ-driven FMT with varying levels of efficacy and po-
tency (Fig. 6), however, full concentration-response
curves could not be established for NECA, dopamine, α-
MSH, IBMX or rolipram. Of the agonists tested, MRE-
269, Bay 60–6583 and forskolin were able to completely
inhibit FMT. All other ligands were able to partially in-
hibit FMT, with maximal levels of inhibition ranging
from 71% of the TGFβ response for AGN205204 to 51%
of the TGFβ response for salmeterol.
Correlation between cAMP and the inhibition of
proliferation and differentiation
Because the assays like the simple, homogenous second
messenger system used here are often utilised in high
Table 3 Potency and intrinsic activity of all ligands for cAMP accumulation and inhibition of proliferation assays, in HLF
Agonist cAMP Proliferation vs serum Proliferation vs PDGF
pEC50 Emax (% max) pEC50 Emax (% max) pEC50 Emax (% max)
Treprostinil 6.82 ± 0.06 101 ± 0.58 6.99 ± 0.27 42.5 ± 5.36 7.53 ± 0.12 63.7 ± 6.39
MRE-269 6.75 ± 0.15 52.9 ± 4.36 NC NC 6.50 ± 0.23 85.7 ± 7.65
Iloprost 7.11 ± 0.34 99.5 ± 7.22 NC NC NC NC
BMY-45778 7.25 ± 0.09 50.0 ± 4.59 ND ND ND ND
Beraprost 6.98 ± 0.08 107 ± 8.99 ND ND ND ND
PGE2 7.34 ± 0.10 85.5 ± 8.64 7.04 ± 0.18 43.1 ± 6.14 8.60 ± 0.08 71.0 ± 3.86
Misoprostol 6.97 ± 0.06 52.4 ± 6.23 6.74 ± 0.10 34.7 ± 0.71 6.13 ± 0.04 94.1 ± 1.59
Butaprost 5.81 ± 0.16 8.76 ± 3.25 7.19 ± 0.38 29.1 ± 7.29 NC NC
AGN-205204 6.62 ± 0.12 49.7 ± 3.84 6.91 ± 0.48 51.3 ± 8.89 7.45 ± 0.25 101 ± 3.71
Formoterol 9.38 ± 0.20 103 ± 4.60 9.58 ± 0.29 37.2 ± 2.64 9.08 ± 0.72 70.1 ± 2.96
Indacaterol 8.58 ± 0.20 83.3 ± 4.47 7.96 ± 0.35 47.9 ± 1.58 8.84 ± 0.28 90.3 ± 5.25
Salbutamol 7.36 ± 0.34 68.9 ± 1.40 7.04 ± 0.57 32.4 ± 5.84 7.98 ± 0.17 69.2 ± 5.53
Salmeterol 9.91 ± 0.16 45.8 ± 3.53 9.58 ± 0.14 37.7 ± 7.33 10.5 ± 0.15 89.2 ± 0.27
α-MSH NC NC NC NC NC NC
NECA 5.39 ± 0.13 47.3 ± 3.40 NC NC 6.94 ± 0.43 37.8 ± 14.7
CGS-21680 NC NC NC NC NC NC
BAY60–6583 6.57 ± 0.06 10.2 ± 2.89 5.30 ± 0.16 100 ± 0.01 5.30 ± 0.12 100 ± 0.01
Dopamine 5.39 ± 0.07 41.2 ± 10.0 ND ND 4.78 ± 0.27 73.5 ± 13.5
Forskolin NC NC 5.28 ± 0.13 74.0 ± 6.70 5.98 ± 0.14 90.8 ± 9.12
IBMX NC NC NC NC NC NC
Rolipram NC NC NC NC NC NC
Potency and intrinsic activity values for a range of Gs-coupled receptor agonists, PDE inhibitors, and forskolin in cAMP accumulation and BrdU inhibition assays in
HLF. For cAMP accumulation intrinsic activity was calculated as a percentage of the maximal forskolin response. For BrdU inhibition intrinsic activity was
calculated as a percentage of maximal proliferation observed with serum or PDGF, as indicated. Data were expressed as means ± SEM for at least 3
independent experiments
NC not calculated due to incomplete curve, ND not determined in this assay
Fig. 3 Fibroblast proliferation. Concentration-dependent increase in
HLF proliferation following treatment with serum or PDGF for 24 h,
assayed using BrdU incorporation. Data were normalized to maximal
proliferation observed with 10% serum, and expressed as mean ±
SEM for 8 independent experiments
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throughput screening to identify novel agonists for cAMP
accumulation, we wanted to explore the relevance of this
method for predicting the inhibition of HLF proliferation
and differentiation. To do this, we generated correlation
plots for maximal levels of cAMP generation against the
maximal inhibition of proliferation or FMT (Fig. 7). There
was no significant correlation between the amount of
cAMP accumulation and the degree of inhibition of
PDGF-mediated proliferation (r2 = 0.06, p = 0.41), or
TGFβ-mediated FMT (r2 = 0.06, p = 0.46). This was most
apparent with formoterol and treprostinil, which despite
generating high levels of cAMP were relatively ineffective
at inhibiting proliferation and differentiation. In contrast,
BAY60–6583 and MRE-269 exhibited higher efficacy for
the inhibition of proliferation and FMT than cAMP
accumulation.
Discussion
IPF is a devastating disease, and with current therapeu-
tics only able to slow disease progression and being as-
sociated with severe side effects, further research in IPF
aetiology and drug discovery is urgently required. A key
feature of IPF is airway remodelling which is driven by
fibroblast proliferation and differentiation. This leads to
the formation of fibroblast and myofibroblast foci that
excrete excessive amounts of extracellular matrix result-
ing in airway stiffening and loss of pulmonary function.
It is this airway remodelling that is associated with
disease severity [2, 22] suggesting that targeting the in-
hibition of key fibroblast activities may lead to novel
therapeutic approaches for IPF. There is an evolving
body of evidence demonstrating cAMP as a potential
target for the treatment of IPF, however it is unclear
Fig. 4 Receptor-mediated inhibition of serum-mediated proliferation. Concentration effect curves for the inhibition of proliferation were determined in
HLF following exposure to a range of agonists targeting the (a) IP receptor, (b) EP receptor, (c) β2 adrenoceptor, (d) other GPCR and (e) non-receptors,
in the presence of an EC80 concentration of serum for 24 h. For each individual experiment, data were normalised to the maximal proliferation
observed with serum, and are expressed as means ± SEM for at least 3 independent experiments
Roberts et al. Respiratory Research  (2018) 19:56 Page 8 of 13
how acute cAMP accumulation is able to affect the
chronic phenotypic responses involved in fibrosis, such
as cell proliferation and differentiation.
Approved therapies and novel approaches undergoing
clinical trials in IPF take the approach of inhibiting a range
of pro-fibrotic stimuli, often GF-RTK combinations that
predominantly signal via the MAPK pathway. Using fibro-
blast proliferation to model aspects of lung fibrosis, we
demonstrated that inhibition of the MAPK pathway com-
pleted blocked PDGF-mediated proliferation, and that
ERK phosphorylation could be completely inhibited by
increasing global cAMP. For this reason, we wanted to ex-
plore the expression of Gs-coupled GPCR in HLF, as well
as their ability to increase cAMP and subsequently inhibit
HLF proliferation and differentiation in order to identify
new targets to treat IPF that will complement existing
therapies.
We observed mRNA expression of a number of differ-
ent Gs-coupled GPCR in fibroblasts, including related
receptor families such as those for prostaglandins (IP, EP2,
EP4) and adenosine (A2A and A2B), as well as the MC1, β2
adrenoceptor and dopamine-1 receptors. Importantly, not
all of these receptors resulted in functional cAMP re-
sponses, as measured by high throughput, homogenous
assay systems. This highlights the need to look not only at
mRNA levels, but protein expression and function as well
to confirm active receptors are present.
To model chronic aspects of IPF we chose to study
HLF proliferation and differentiation, as HLF are key
mediators of fibrosis and contain human receptors and
Fig. 5 Receptor-mediated inhibition of PDGF-mediated proliferation. Concentration effect curves for the inhibition of proliferation were determined in
HLF following exposure to a range of agonists targeting the (a) IP receptor, (b) EP receptor, (c) β2 adrenoceptor, (d) other GPCR and (e) non-receptors,
in the presence of an EC80 concentration of PDGF for 24 h. For each individual experiment, data were normalised to the maximal proliferation
observed with PDGF, and are expressed as means ± SEM for at least 3 independent experiments
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Fig. 6 Receptor-mediated inhibition of TGFβ-mediated FMT. Concentration effect curves for the inhibition of FMT were determined in HLF following
exposure to a range of agonists targeting the (a) IP or EP receptors, (b) β2 adrenoceptor, (c) other GPCR and (d) non-receptors, in the presence of an
EC80 concentration of TGFβ for 48 h. For each individual experiment, data were normalised to the maximal levels of FMT observed with TGFβ, and are
expressed as means ± SEM for 4 independent experiments
Fig. 7 Correlation plot. Correlation between global cAMP accumulation and maximal inhibition of PDGF-mediated proliferation (a) or TGFβ-
mediated FMT (b). Pearson correlation, dashed line = line of unity
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signalling proteins at relevant levels. Proliferation was
monitored using two complimentary methods, BrdU in-
corporation into newly synthesized DNA of actively pro-
liferating cells, and direct cell counting. Differentiation
was monitored using an FMT assay that measures the
increased expression of αSMA that indicates a myofibro-
blast phenotype. Using the BrdU incorporation assay we
were able to quantify proliferation in response to both
PDGF and serum (which contains multiple growth fac-
tors and proliferative stimuli) at an earlier stage com-
pared to the cell counting method. This is likely due to
the different sensitivities of the assays as well as the time
course of responses being measured. We also observed
that full concentration-response curves for the inhibition
of cell counting could not be obtained for all ligands.
For this reason, we focused on the BrdU incorporation
and FMT assays to explore the responses further.
Using these models, we have demonstrated that selected
agonists for the IP, β2, EP2, EP4, and A2B receptors, as well
as forskolin, an activator of AC, were able to robustly in-
hibit HLF proliferation and differentiation. Interestingly,
some agonists such as MRE-269, AGN205204 and BAY
60–6583 were able to fully inhibit either proliferation or
FMT, despite being partial agonists for cAMP accumula-
tion. This demonstrates that many of the agonists we have
tested in this study have the potential to inhibit multiple
processes that contribute to IPF clinically. It is important
to note however that these studies were performed on fi-
broblasts from healthy donors, and therefore these results
should be confirmed in fibroblasts from IPF patients,
which may differ in their established phenotype.
We were able to demonstrate using bother fibroblast
proliferation and differentiation that cAMP accumula-
tion does not correlate with the degree of inhibition of
chronic phenotypic responses. This highlights the im-
portance of developing novel treatments for IPF on the
basis of their chronic effects rather than acute cAMP
responses. For example, although iloprost has been
described as a potential treatment for IPF due to its
protective effects against bleomycin-induced pulmonary
fibrosis in mice [23], our data suggests this may not be
the optimal IP agonist for the treatment of IPF.
A number of the GPCR we identified here have previ-
ously been implicated in the treatment of IPF or other
chronic lung diseases. The endogenous EP receptor
agonist PGE2 has been shown to inhibit cellular markers
of fibrosis [14, 16], and its synthetic analogue 16, 16-
dimethyl-PGE2 protects against bleomycin induced in-
jury [24]. This coupled with diminished PGE2 signalling
in lung fibrosis [25], and the strong inhibition of prolif-
eration we observe with selective agonists suggests that
EP2 &/or EP4 agonists are strong candidates for novel
IPF treatments. Recent studies have also identified the
A2B receptor as an important target in the regulation of
both acute and chronic lung disease, with agonists being
considered for the treatment of acute lung injury and
antagonists being considered for the treatment of
chronic lung diseases [26–28]. In agreement with these
findings, we observed that the selective A2B agonist BAY
60–6583, although not very potent, showed robust in-
hibition of HLF proliferation.
Currently, inhaled β2 adrenoceptor agonists are widely
used for the treatment of lung diseases such as chronic
obstructive pulmonary disease (COPD), providing relief
by inducing bronchodilation of airway smooth muscle.
We have shown here that the long acting β2 adrenocep-
tor agonists’ salmeterol and indacaterol may also act as
anti-fibrotic agents in IPF through the robust inhibition
of HLF proliferation and differentiation.
Although we did not observe any acute cAMP accu-
mulation with the PDE inhibitor IBMX, we did observe
some inhibition of both proliferation and FMT at higher
concentrations. In the isolated fibroblasts there may not
be sufficient basal cAMP turnover in order for PDE in-
hibitors to substantially increase levels of cAMP during
the shorter cAMP assay, but with the extended incuba-
tion for the phenotypic assays (24 or 48 h), IBMX may
be able to cause some accumulation of cAMP that is
driving this inhibitory effect. In support of this, PDE in-
hibitor use is being explored for IPF and they have been
shown to be effective in the bleomycin model [18, 19]. It
would therefore be interesting to determine whether co-
administration with GPCR agonists could further boost
the anti-proliferative capacity of the agonists tested here.
The mechanisms behind the apparent disconnect we
observed between acute cAMP accumulation and inhib-
ition of chronic phenotypic responses is not yet clear,
however there are a number of factors that need to be
considered. Firstly, proliferation and differentiation were
monitored over a longer time period than the cAMP accu-
mulation assays, so it is possible that the agonists tested
were degrading over time leading to loss of response. We
have previously demonstrated that for treprostinil and
MRE-269 > 90% of the original concentration of agonist
remains after 24 h incubation with HLF (unpublished
data), suggesting that it is unlikely that ligand degradation
is contributing to the effect we have seen.
Another aspect of GPCR signalling that may be contrib-
uting to the responses we have observed is the ability to
signal through multiple G proteins or effector molecules.
It has now been well characterized that β-arrestin, once
recruited to a GPCR, may initiate a cascade of G protein-
independent signalling [29], the best characterized of
which is the MAPK/ERK cascade. In these cells activation
of cAMP signalling leads to inhibition of proliferation,
most likely via inhibition of the ERK phosphorylation.
This suggests that this promiscuous signalling is unlikely
to be contributing to the disconnect we observed between
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cAMP and inhibition of proliferation, although it should
be explored further. Forskolin was able to robustly inhibit
both fibroblast proliferation and differentiation, further
supporting a direct role for the cAMP pathway in the in-
hibition of these chronic phenotypic responses. It may be
that the spatial or temporal control of these cAMP signals
is more important in regulating downstream, chronic ef-
fects rather than the absolute levels of cAMP generated.
The temporal characteristics of the cAMP response can
be controlled directly through the kinetics or duration of
the cAMP response, or through time-dependent internal-
ization and desensitization of activated receptors. Agonists
such as treprostinil and iloprost which are full agonists in
the cAMP accumulation assay may undergo a higher de-
gree of desensitization than the partial agonist MRE-269.
This could explain why there is a reversal of intrinsic activ-
ity for these ligands in the two assays. However, recent
evidence from chronic cAMP studies suggests that regard-
less of their efficacy, all agonists will produce the same rela-
tive degree of functional desensitization [30]. In support of
this, indacaterol, which elicits 80% maximal response in
cAMP is as effective at inhibiting proliferation as the lower
efficacy agonist salmeterol, which elicits a 40% maximal
cAMP response. Interestingly, both these compounds are
long-acting β2 adrenoceptor agonists, which suggests a role
for signalling kinetics in mediating chronic phenotypic
events. This has been demonstrated previously for the regu-
lation of gene transcription after GPCR activation, where
the kinetics or duration of second messenger responses was
shown to drive transcriptional activity [31, 32].
Compartmentalized cAMP signalling may also contrib-
ute to receptor/ligand-dependent downstream effects. Se-
lective activation of specific intracellular pools of cAMP
can occur through physical intracellular barriers, such as
the A-kinase-anchoring proteins (AKAP) [33–35], or
through persistent signalling of agonist-receptor com-
plexes after internalization. This persistent signalling has
been described for the Gi-coupled S1P1 receptor [36] and
more recently with the β2 adrenoceptor [37]. Further stud-
ies are required to determine if the duration and location
of the cAMP signalling, rather than the magnitude, is
important for long-term phenotypic responses.
Conclusion
In conclusion, in these studies we have demonstrated
that selected agonists at the IP, β2, EP2, EP4, and A2B
receptors have the potential to inhibit pro-fibrotic pro-
cesses such as fibroblast proliferation and differentiation,
implying a potential for disease modifying effects in IPF.
From these results it appears that although the cAMP
response is important in driving the anti-fibrotic effects
we have observed, there appears to be a threshold of
cAMP that is required to inhibit proliferation and differ-
entiation over which any further increases of cAMP do
not drive further inhibition. For this reason, the magni-
tude of acute, global cAMP accumulation does not ac-
curately predict the degree of inhibition of proliferation
or differentiation suggesting additional factors, such as
the spatio-temporal control of cAMP are important.
Further research is required to understand this discon-
nect, which will aid in the discovery of novel, therapeut-
ically beneficial treatments for IPF.
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